News Archive

November 30, 2023

Biotech Consolidation: Not Really Happening

After the bursting of the pandemic biotech bubble, talk of industry consolidation was ubiquitous. The sector had pushed out too many IPOs during the go-go years, leading to too many public biotech companies, with sub-scale enterprises, and wasteful crowding in lots of therapeutic categories.
  • LifeSciVC
Read more
November 28, 2023

Darkest Before Dawn: A Story Of Biotech Optimism In A Tough Market

Earlier this year, Nimbus closed the sale of our allosteric TYK2 program, which was acquired by Takeda for $4 billion upfront. By Jeb Keiper, CEO of Nimbus Therapeutics, as part of the From The Trenches feature of LifeSciVC.
  • From the Trenches
Read more
November 17, 2023

Atlas Venture 2023 Year In Review

This month we held our 2023 Annual General Meeting for our fund’s investors and our Atlas Venture Retreat with industry executives. As in the past, we’ve kicked off each of these meetings with our Year In Review. Watch the presentation at the link in this article.
  • LifeSciVC
Read more
November 16, 2023

Q32 Bio to take Homology Medicines’ Nasdaq spot to fund PhII trials in autoimmune, inflammatory conditions

The reverse mergers are flowing. Q32 Bio will take Homology Medicines’ place on the Nasdaq, the companies said Thursday morning, and the biologics maker expects to have about $115 million at the time their deal closes, likely in the first quarter of 2024.
  • Portfolio Company News
Read more
October 26, 2023

Triveni Bio launches with $92M Series A to fund eczema antibody treatment

Triveni Bio has raised $92 million in a Series A financing round as it aims to move its atopic dermatitis antibody into the clinic.
  • Portfolio Company News
Read more